Biblio

Author Title [ Type

] Year

Filters: Author is Feng, Ru [Clear All Filters]

Journal Article

Zhang X, Gale RPeter, Liu B, Huang J, Zhang Y, Du X, Weng J, Li W, Xu N, Liu X, et al. Validation of the imatinib-therapy failure model. Leukemia. 2023.

Zhao P, Hou M, Liu Y, Liu H-X, Bin Huang R-, Yao H-X, Niu T, Peng J, Jiang M, Han Y-Q, et al. Risk stratification and outcomes of intracranial hemorrhage in patients with immune thrombocytopenia under 60 years of age. Platelets. 2020:1-9.

Wu Y-J, Hou M, Liu H-X, Peng J, Ma L-M, Yang L-H, Feng R, Liu H, Liu Y, Feng J, et al. A risk score for predicting hospitalization for community-acquired pneumonia in ITP using nationally representative data. Blood Adv. 2020;4(22):5846-5857.

Zhang X-H, Wang G-X, Zhu H-H, Liu Y-R, Xu L-P, Han W, Chen H, Chen Y-H, Wang F-R, Wang J-Z, et al. Recruitment of CD8(+) T cells into bone marrow might explain the suppression of megakaryocyte apoptosis through high expression of CX3CR1(+) in prolonged isolated thrombocytopenia after allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2015.

An Z-Y, Wu Y-J, Hou Y, Mei H, Nong W-X, Li W-Q, Zhou H, Feng R, Shen J-P, Peng J, et al. A life-threatening bleeding prediction model for immune thrombocytopenia based on personalized machine learning: a nationwide prospective cohort study. Sci Bull (Beijing). 2023.

Yang S, Zhang X, Gale RPeter, Du X, Chen C-Y, Weng J-Y, Huang J, Li F, Zeng Y, Xiao Z, et al. Imatinib compared with second-generation tyrosine kinase-inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase. Am J Hematol. 2023.

Wu M, Huang F, Jiang X, Fan Z, Zhou H, Liu C, Jiang Q, Zhang Y, Zhao K, Xuan L, et al. Herpesvirus-Associated Central Nervous System Diseases after Allogeneic Hematopoietic Stem Cell Transplantation. PLoS One. 2013;8(10):e77805.

Zhang Y, Song Q, Cassady K, Lee M, Tang H, Zheng M, Wang B, Schones DE, Fu Y-X, Riggs AD, et al. Blockade of trans PD-L1 interaction with CD80 augments antitumor immunity. Proc Natl Acad Sci U S A. 2023;120(16):e2205085120.

Huang Q-S, Liu Y, Wang J-B, Peng J, Hou M, Liu H, Feng R, Wang J-W, Xu L-P, Wang Y, et al. All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Haematol. 2021;8(10):e688-e699.